NF‐κB has been linked to bone marrow microenvironment alterations, cell growth and drug resistance in tumour cells31, 32, 33; notably, NF‐κB was also activated in RPMI 8226 cells after EPOX treatment. The gene discussed is NFKB1; the disease is neoplasm.